Recent And Upcoming FDA Advisory Committee Meetings
Executive Summary
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
You may also be interested in...
RoxyBond Gets US Advisory Panel OK For Abuse-Deterrent Claim Despite Excipient Concerns
Members unanimously endorse product and mostly supported abuse-deterrent language; several panelists suggest warning about possible harmful effects of excipients by abusing product intravenously.
Novo Hemophilia Drug's Postmarket Monitoring Plan Not Robust Enough – US Panel
FDA advisory committee members support approval of investigational hemophilia B treatment nonacog beta pegol but say Novo Nordisk needs more systematic approach to monitoring for neurological and developmental adverse events.
What’s Next For Antacid/Analgesic OTCs After Negative US FDA Panel?
Nonprescription Drug and the Drug Safety and Risk Management advisory committees jointly vote 15-5 that combining antacid with aspirin, acetaminophen or other analgesic ingredients is not a combination that should be allowed under an OTC monograph.